875573-42-5

Basic information

• Product Name: Thiazolo[4,5-b]pyridine-2-carboxylic acid
• Synonyms: Thiazolo[4,5-b]pyridine-2-carboxylic acid
• CAS NO: 875573-42-5
• Molecular Formula: C7H4N2O2S
• Molecular Weight: 180.18386
• Mol File: 875573-42-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Thiazolo[4,5-b]pyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazolo[4,5-b]pyridine-2-carboxylic acid(875573-42-5)
• EPA Substance Registry System: Thiazolo[4,5-b]pyridine-2-carboxylic acid(875573-42-5)

Safety Data

• Hazardous Substances Data: 875573-42-5(Hazardous Substances Data)

Upstream product

• 175659-41-3 2-methylthiazolo[4,5-b]pyridine 

Relevant articles and documents

PRODUCTION METHOD OF BENZOTHIAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide: a production method of a benzothiazole derivative; as well as a production method of a polymerizable compound produced from the benzothiazole derivative; a polymerizable composition including the polymerizable compound; a polymer obtained by polymerizing the polymerizable composition; and an optical isomer utilizing the polymer. SOLUTION: A production method of a compound represented by the following general formula (III) is provided, and also a production method of a polymerizable compound produced from the compound represented by the general formula (III), a polymerizable composition, a polymer obtained by polymerizing the polymerizable composition, and an optical isomer utilizing the polymer are provided. When the polymerizable composition containing the compound is polymerized and the obtained film-like polymer is irradiated with ultraviolet light, change of color and change of phase difference scarcely take place. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS

Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifiying biofilm formation inhibitors.

Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

Serine protease factor xa (fXa) inhibitor 1 showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that 1 had low metabolic stability against human liver microsomes. To improve the metabolic stability, we att